Singapore, April 23, 2008: Quintiles has appointed three new practice leaders and a business development head as part of its expanding Quintiles Consulting business, which provides pharmaceutical, biotech and medical device companies with strategic guidance to maximize potential and minimize risk from early discovery through commercialization.

 

Quintiles is expanding its current services and building a premier global consulting organization to provide strategic, operational and technical advice to pharmaceutical, biotechnology and medical device companies. The organization will focus on market leading issues and address client needs in three practice areas: Product Development and Commercialization, Regulatory and Quality, and Market Access.

 

John Doyle will lead the US Market Access practice, focusing on market access strategy, health economic assessments, outcomes research, and pricing and reimbursement strategy and support.

 

Adrian K. McKemey has been hired to lead Quintiles Consulting’s Product Development and Commercialization practice, focusing on business transformation, portfolio management, risk partnering, scenario planning and outsourcing strategies.

 

McKemey was most recently a Principal with the Boston Consulting Group (BCG), working in the Health Care practice and the BCG Strategy Institute.

 

Jim Featherstone will grow the Product Development and Commercialization practice in Europe, as well as oversee and expand the existing regulatory and quality consulting services in Europe.

 

Featherstone joins Quintiles from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice.

 

Matt Eberhart will be responsible for establishing a global business development framework, leading the business development efforts in the US and serving as the internal liaison to the broader Quintiles organization.